Overview

A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC

Status:
Withdrawn
Trial end date:
2022-10-30
Target enrollment:
Participant gender:
Summary
This research study is studying an investigational drug, NC318, as a possible treatment for subjects with advanced or metastatic non-small cell lung cancer in combination with chemotherapy
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
NextCure, Inc.
Treatments:
Carboplatin
Docetaxel
Paclitaxel
Pemetrexed